Kidney transplant patients with long-term graft survival have altered expression of molecules associated with T-cell activation

被引:24
作者
Alvarez, CM
Paris, SC
Arango, L
Arbelaez, M
Garcia, LF
机构
[1] Univ Antioquia, Fac Med, Grp Inmunol Celular & Inmunogenet, Medellin, Colombia
[2] Univ Antioquia, Ctr Invest Med, Unidad Citomet Flujo, Medellin, Colombia
[3] Univ Antioquia, Fac Med, Dept Med Interna, Secc Nefrol, Medellin, Colombia
关键词
co-stimulation; kidney transplant; regulatory T cells; T cells;
D O I
10.1097/01.TP.0000140968.17770.C1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Patients with long-term functioning organ allografts may have developed different mechanisms that explain the lack of graft rejection. However, it is not known how these mechanisms interplay or whether one of them predominates in such situations. Methods. The authors analyzed the expression of T-cell surface molecules involved in alloantigen recognition, signal transduction, co-stimulation, and activation markers on circulating T cells from patients with normal kidney function 10 or more years after transplantation, short-term survival (1-4 years), and chronic rejection and from healthy adults. The percentage and the median fluorescent intensity of each marker were determined by flow cytometry. Proliferative response against specific and third-party donors and mitogenic stimulation were also determined. Results. Peripheral blood lymphocytes from patients with long-term surviving kidneys had decreased expression of T-cell receptor (TCR)-alphabeta (P<0.01), CD3epsilon (P<0.05), and CD3 zeta-chains (P<0.001); diminished percentages of CD4(+)CD28(+) (P<0.001) cells; and increased expression of CTLA-4(+) (P<0.01) on CD3(+) cells. CD4(+)CD25(+)CD69(+) cells were also increased in long-term surviving patients. Long-term surviving patients had decreased donor-specific proliferative responses. Conclusions. The decreased expression of TCR-alphabeta and epsilon- and xi-chains on circulating T cells of long-term surviving patients suggests that these cells may have defects in alloantigen recognition or signal transduction that may result in decreased numbers of T cells expressing co-stimulatory molecules and activation markers as well as a decreased specific proliferative response. The decrease in the percentage of CD28(+) cells and the increase in CD4(+)CD25(+)CD69(+) cells suggest that regulatory mechanisms of the immune response are still active in such patients.
引用
收藏
页码:1541 / 1547
页数:7
相关论文
共 26 条
[1]   Altered T-cell receptor+CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-β-treated alloreactive T cells that do not induce graft-versus-host disease [J].
Boussiotis, VA ;
Chen, ZM ;
Zeller, JC ;
Murphy, WJ ;
Berezovskaya, A ;
Narula, S ;
Roncarolo, MG ;
Blazar, BR .
BLOOD, 2001, 97 (02) :565-571
[2]   The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses [J].
Carreno, BM ;
Collins, M .
ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :29-53
[3]  
Dong V M, 1999, Pediatr Transplant, V3, P181, DOI 10.1034/j.1399-3046.1999.00042.x
[4]   Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection [J].
Dong, VM ;
Yuan, XL ;
Coito, AJ ;
Waaga, AM ;
Sayegh, MH ;
Chandraker, A .
TRANSPLANTATION, 2002, 73 (08) :1310-1317
[5]  
Eagar TN, 2002, EUR J IMMUNOL, V32, P972, DOI 10.1002/1521-4141(200204)32:4<972::AID-IMMU972>3.3.CO
[6]  
2-D
[7]   CD4+CD25+ T cells facilitate the induction of T cell anergy [J].
Ermann, J ;
Szanya, V ;
Ford, GS ;
Paragas, V ;
Fathman, CG ;
Lejon, K .
JOURNAL OF IMMUNOLOGY, 2001, 167 (08) :4271-4275
[8]   Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69) [J].
Fehse, B ;
Frerk, O ;
Goldmann, M ;
Bulduk, M ;
Zander, AR .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) :644-651
[9]   Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy [J].
Gratama, JW ;
Zea, AH ;
Bolhuis, RLH ;
Ochoa, AC .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1999, 48 (05) :263-269
[10]   Cutting edge: Targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells [J].
Hwang, KW ;
Sweatt, WB ;
Brown, IE ;
Blank, C ;
Gajewski, TF ;
Bluestone, JA ;
Alegre, ML .
JOURNAL OF IMMUNOLOGY, 2002, 169 (02) :633-637